MAP3K5 and cancer: OA is reported to inhibit metastasis, angiogenesis, and invasion in different cancers [10], while it induces programmed cell death in different cancer cell lines, such as osteosarcoma, liver, gastric, breast, prostate, pancreatic, colorectal, and bladder cancer cells [10] via enhancement of p38 MAPK, ASK1, ROS, and inhibition of signalling pathways, such as S6K, PI3K, mTOR, Akt, and NF-κB in time- and concentration-dependent fashion [10].